subscribeSubscribe
price-trendAsk Us
Active Biotech: Year End Report 2021

Active Biotech: Year End Report 2021
GLOBENEWSWIRE
09 Feb 2022
Share Share
First subject dosed in phase I clinical study with eye-drop laquinimod  

First subject dosed in phase I clinical study with eye-drop laquinimod  
GLOBENEWSWIRE
10 Dec 2021
Share Share
CDMO Famar and Active Biotech Ink Clinical Manufacturing Deal

CDMO Famar and Active Biotech Ink Clinical Manufacturing Deal
PRESS RELEASE
04 Feb 2021
Share Share
Teva drops development of laquinimod

Teva drops development of laquinimod
Selina McKee PHARMA TIMES
07 Sep 2018
Share Share
Active Biotech regains rights of laquinimod from Teva

Active Biotech regains rights of laquinimod from Teva
BIOSPECTRUM
06 Sep 2018
Share Share
Teva finally dumps laquinimod, ending failure-riddled saga

Teva finally dumps laquinimod, ending failure-riddled saga
Nick Paul Taylor FIERCE BIOTECH
05 Sep 2018
Share Share
Teva’s one-time blockbuster-to-be laquinimod fails yet again

Teva’s one-time blockbuster-to-be laquinimod fails yet again
John Carroll ENDPTS
31 Jul 2018
Share Share